• Profile
Close

Radiotherapy vs transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): An open-label, phase 2, randomised trial

The Lancet Oncology Aug 17, 2019

Nichols AC, Theurer J, Prisman E, et al. - In an investigator-initiated, multicenter, international, open-label, parallel-group, phase 2, randomized study, researchers compared quality of life (QOL) 1 year posttreatment among patients aged 18 years or older with Eastern Cooperative Oncology Group scores of 0–2, and with T1–T2, N0–2 (≤ 4 cm) oropharyngeal squamous cell carcinoma (OPSCC) tumor types randomized (1:1) to radiotherapy (70 Gy, with chemotherapy if N1–2) vs transoral robotic surgery plus neck dissection (with or without adjuvant chemoradiotherapy, based on pathology). In Canada and Australia, patients were enrolled at six hospitals. Randomization of patients, post-stratification by p16 status, was done using a computer-generated randomization list with permuted blocks of four. At 1-year posttreatment, better swallowing-related QOL scores were reported in patients who had radiotherapy, although the difference was not clinically meaningful. The groups showed different toxicity patterns. Informing patients with OPSCC regarding both treatment options was recommended.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay